A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Biliary Cholangitis

Trial Profile

A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Biliary Cholangitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs LJN 452 (Primary)
  • Indications Biliary cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Dec 2017 to 5 May 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 19 Oct 2015 Planned number of patients changed from 90 to 40, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top